The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a definitive contract valued at $12.5 billion to Pfizer Inc. for the manufacturing and delivery of 10 million treatment courses of the oral protease inhibitor PF-07321332. This award was made under the Joint PEO-CBRND & BARDA Commercial Solutions Opening solicitation seeking proposals to produce a minimum of 100,000 treatment courses of advanced SARS-CoV-2 medical countermeasures by March 2021 to treat the indicated U.S. population. The contract has a period of performance from November 2021 through March 2023 with firm fixed pricing. Pfizer will deliver the requested oral antiviral drug from its New York location to address this urgent need for COVID-19 therapeutics under JPEO-CBRND and BARDA programs.
Generated 12/29/23, 4:09 PM